Anaptysbio (ANAB) Cash from Investing Activities Growth (3y) (2019 - 2026)
Powered by 
Analysis
Anaptysbio (ANAB) Cash from Investing Activities Growth (3y) (2019 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.26 Bn | 131.41 Bn | 2.84 Bn | 46.78% |
| 2 | Regeneron Pharmaceuticals | 85.64 Bn | 77.64 Bn | 3.93 Bn | 66.14% |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.83 Bn | 52.69 Bn | 52.00 Mn | -44.69% |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | - |
| 6 | BeOne Medicines | 39.94 Bn | 34.84 Bn | 1.53 Bn | -39.73% |
| 7 | Alnylam Pharmaceuticals | 35.19 Bn | 31.88 Bn | 992.69 Mn | -246.81% |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | -53.57% |
| 9 | Insmed | 27.35 Bn | 26.19 Bn | 358.27 Mn | 27.84% |
| 10 | Anaptysbio | 1.62 Bn | 1.33 Bn | - | -25.73% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -25.73% |
| Dec 31, 2025 | 50.65% |
| Sep 30, 2025 | 73.07% |
| Jun 30, 2025 | 35.95% |
| Mar 31, 2025 | 26.98% |
| Dec 31, 2024 | 23.90% |
| Sep 30, 2024 | 75.53% |
| Jun 30, 2024 | -27.33% |
| Mar 31, 2024 | 6.55% |
| Dec 31, 2023 | 139.09% |
| Sep 30, 2023 | 86.38% |
| Jun 30, 2023 | -31.45% |
| Mar 31, 2023 | 99.52% |
| Dec 31, 2022 | 74.65% |
| Sep 30, 2022 | -36.47% |
| Jun 30, 2022 | -47.77% |
| Mar 31, 2022 | -225.23% |
| Dec 31, 2021 | 26.23% |
| Sep 30, 2021 | -23.92% |
| Jun 30, 2021 | 143.27% |